智通财经APP获悉，巨子生物(02367)涨超5%，高见63.3港元创上市以来新高。截至发稿，涨5.69%，报63.15港元，成交额1.43亿港元。
消息面上，近日，巨子生物旗下品牌可复美推出了首个针对修护皮肤热损伤的系列产品——可复美帧域密修系列。该系列不仅能为医美全周期护理提供解决方案，同时还兼顾日常控纹、紧塑、焕亮等多重功效需求。值得关注的是，可复美帧域密修系列的核心功效成分首次应用了巨子生物全新研发的Ⅳ型热塑胶原（全称为：天然序列重组Ⅳ型胶原蛋白（α1-P1441-P1669））。
花旗发布研报称，该系列以其新的专利重组胶原蛋白成分，针对热损伤后的肌肤护理，尤其是光电治疗后的护理，令公司的修护产品线从基础和一般修护，拓展到更专业及精准护理领域，有助带来新收入来源、巩固其以科学为导向的产品定位，并建立了专业品牌形象。给予巨子生物“买入”评级，基于2025年预测市盈率约25倍，将目标价由61港元上调至68.2港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.